Our findings support further exploration of newer CDK9 inhibitors which are more specific and likely to cause lower toxicity with therapeutic doses in patients with esophageal adenocarcinoma compared to the previously used CDK9 inhibitors. This evidence concerns the gene CDK9 and esophageal adenocarcinoma.